|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: BOD1 |
Gene summary for BOD1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | BOD1 | Gene ID | 91272 |
| Gene name | biorientation of chromosomes in cell division 1 | |
| Gene Alias | FAM44B | |
| Cytomap | 5q35.2 | |
| Gene Type | protein-coding | GO ID | GO:0000070 | UniProtAcc | Q96IK1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 91272 | BOD1 | C57 | Human | Oral cavity | OSCC | 2.92e-04 | 3.76e-01 | 0.1679 |
| 91272 | BOD1 | C06 | Human | Oral cavity | OSCC | 4.90e-11 | 1.51e+00 | 0.2699 |
| 91272 | BOD1 | C07 | Human | Oral cavity | OSCC | 6.10e-05 | 1.17e+00 | 0.2491 |
| 91272 | BOD1 | C08 | Human | Oral cavity | OSCC | 2.30e-58 | 1.12e+00 | 0.1919 |
| 91272 | BOD1 | C09 | Human | Oral cavity | OSCC | 2.40e-08 | 3.58e-01 | 0.1431 |
| 91272 | BOD1 | LN22 | Human | Oral cavity | OSCC | 5.29e-03 | 6.78e-01 | 0.1733 |
| 91272 | BOD1 | LN46 | Human | Oral cavity | OSCC | 3.18e-11 | 7.97e-01 | 0.1666 |
| 91272 | BOD1 | LP15 | Human | Oral cavity | LP | 7.58e-04 | 1.06e+00 | 0.2174 |
| 91272 | BOD1 | LP17 | Human | Oral cavity | LP | 2.29e-02 | 7.12e-01 | 0.2349 |
| 91272 | BOD1 | SYSMH1 | Human | Oral cavity | OSCC | 8.33e-11 | 3.05e-01 | 0.1127 |
| 91272 | BOD1 | SYSMH2 | Human | Oral cavity | OSCC | 1.77e-19 | 6.91e-01 | 0.2326 |
| 91272 | BOD1 | SYSMH3 | Human | Oral cavity | OSCC | 4.20e-19 | 6.38e-01 | 0.2442 |
| 91272 | BOD1 | SYSMH4 | Human | Oral cavity | OSCC | 4.20e-11 | 2.01e-01 | 0.1226 |
| 91272 | BOD1 | SYSMH5 | Human | Oral cavity | OSCC | 3.84e-02 | 1.40e-01 | 0.0647 |
| 91272 | BOD1 | SYSMH6 | Human | Oral cavity | OSCC | 1.94e-11 | 3.27e-01 | 0.1275 |
| 91272 | BOD1 | P4_S8_cSCC | Human | Skin | cSCC | 8.65e-05 | 7.28e-02 | -0.3095 |
| 91272 | BOD1 | P1_cSCC | Human | Skin | cSCC | 7.00e-10 | 5.17e-01 | 0.0292 |
| 91272 | BOD1 | P2_cSCC | Human | Skin | cSCC | 3.20e-10 | 4.35e-01 | -0.024 |
| 91272 | BOD1 | P4_cSCC | Human | Skin | cSCC | 5.91e-04 | 1.74e-01 | -0.00290000000000005 |
| 91272 | BOD1 | P10_cSCC | Human | Skin | cSCC | 1.59e-09 | 4.81e-01 | 0.1017 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0010563 | Colorectum | AD | negative regulation of phosphorus metabolic process | 130/3918 | 442/18723 | 1.26e-05 | 2.76e-04 | 130 |
| GO:0045936 | Colorectum | AD | negative regulation of phosphate metabolic process | 129/3918 | 441/18723 | 1.81e-05 | 3.76e-04 | 129 |
| GO:0016311 | Colorectum | AD | dephosphorylation | 123/3918 | 417/18723 | 1.84e-05 | 3.82e-04 | 123 |
| GO:0006470 | Colorectum | AD | protein dephosphorylation | 88/3918 | 281/18723 | 2.56e-05 | 4.89e-04 | 88 |
| GO:0035303 | Colorectum | AD | regulation of dephosphorylation | 46/3918 | 128/18723 | 6.20e-05 | 1.04e-03 | 46 |
| GO:0035304 | Colorectum | AD | regulation of protein dephosphorylation | 33/3918 | 90/18723 | 4.23e-04 | 4.77e-03 | 33 |
| GO:0010921 | Colorectum | AD | regulation of phosphatase activity | 30/3918 | 84/18723 | 1.24e-03 | 1.09e-02 | 30 |
| GO:0043666 | Colorectum | AD | regulation of phosphoprotein phosphatase activity | 21/3918 | 58/18723 | 5.25e-03 | 3.47e-02 | 21 |
| GO:0035308 | Colorectum | AD | negative regulation of protein dephosphorylation | 14/3918 | 34/18723 | 5.86e-03 | 3.69e-02 | 14 |
| GO:00105632 | Colorectum | MSS | negative regulation of phosphorus metabolic process | 118/3467 | 442/18723 | 1.18e-05 | 2.77e-04 | 118 |
| GO:00459362 | Colorectum | MSS | negative regulation of phosphate metabolic process | 117/3467 | 441/18723 | 1.74e-05 | 3.84e-04 | 117 |
| GO:00353032 | Colorectum | MSS | regulation of dephosphorylation | 41/3467 | 128/18723 | 1.64e-04 | 2.33e-03 | 41 |
| GO:00353042 | Colorectum | MSS | regulation of protein dephosphorylation | 30/3467 | 90/18723 | 5.58e-04 | 6.19e-03 | 30 |
| GO:00064702 | Colorectum | MSS | protein dephosphorylation | 73/3467 | 281/18723 | 1.15e-03 | 1.12e-02 | 73 |
| GO:00163112 | Colorectum | MSS | dephosphorylation | 101/3467 | 417/18723 | 1.98e-03 | 1.70e-02 | 101 |
| GO:00513461 | Colorectum | MSS | negative regulation of hydrolase activity | 92/3467 | 379/18723 | 2.85e-03 | 2.22e-02 | 92 |
| GO:00109212 | Colorectum | MSS | regulation of phosphatase activity | 26/3467 | 84/18723 | 4.06e-03 | 2.95e-02 | 26 |
| GO:00436662 | Colorectum | MSS | regulation of phosphoprotein phosphatase activity | 19/3467 | 58/18723 | 6.69e-03 | 4.38e-02 | 19 |
| GO:00163113 | Colorectum | FAP | dephosphorylation | 95/2622 | 417/18723 | 7.07e-07 | 3.32e-05 | 95 |
| GO:00064704 | Colorectum | FAP | protein dephosphorylation | 69/2622 | 281/18723 | 1.47e-06 | 6.39e-05 | 69 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| BOD1 | SNV | Missense_Mutation | novel | c.530N>A | p.Pro177His | p.P177H | Q96IK1 | protein_coding | deleterious(0) | benign(0.293) | TCGA-A6-2672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| BOD1 | SNV | Missense_Mutation | novel | c.206G>A | p.Arg69His | p.R69H | Q96IK1 | protein_coding | deleterious(0.01) | probably_damaging(0.974) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| BOD1 | SNV | Missense_Mutation | novel | c.527N>G | p.Asp176Gly | p.D176G | Q96IK1 | protein_coding | deleterious(0.01) | benign(0) | TCGA-AA-3949-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| BOD1 | SNV | Missense_Mutation | novel | c.327N>A | p.Asn109Lys | p.N109K | Q96IK1 | protein_coding | deleterious(0.01) | probably_damaging(0.962) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| BOD1 | SNV | Missense_Mutation | rs747435012 | c.517N>A | p.Glu173Lys | p.E173K | Q96IK1 | protein_coding | tolerated(0.08) | benign(0.089) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| BOD1 | SNV | Missense_Mutation | rs758005393 | c.254N>C | p.Leu85Pro | p.L85P | Q96IK1 | protein_coding | deleterious(0.02) | benign(0.333) | TCGA-BG-A0VZ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
| BOD1 | SNV | Missense_Mutation | rs565588980 | c.541T>A | p.Ser181Thr | p.S181T | Q96IK1 | protein_coding | tolerated(0.09) | benign(0.014) | TCGA-D1-A175-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
| BOD1 | SNV | Missense_Mutation | novel | c.425N>G | p.Asn142Ser | p.N142S | Q96IK1 | protein_coding | tolerated(0.13) | possibly_damaging(0.518) | TCGA-BC-A8YO-01 | Liver | liver hepatocellular carcinoma | Female | >=65 | III/IV | Targeted Molecular therapy | sorafenib | PD |
| BOD1 | SNV | Missense_Mutation | novel | c.505N>A | p.Pro169Thr | p.P169T | Q96IK1 | protein_coding | tolerated(0.05) | possibly_damaging(0.469) | TCGA-18-3419-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| BOD1 | insertion | Frame_Shift_Ins | novel | c.486dupA | p.Ala163SerfsTer34 | p.A163Sfs*34 | Q96IK1 | protein_coding | TCGA-VQ-A94U-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |